Elranatamab + Cyclophosphamide
Phase 2 Trial of Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 26 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Pfizer
- Tags
- Bispecific Antibody, Chemotherapy, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2231
- NCT Identifier
- NCT07454382
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.